Stock Report

All about this stock under one free report Last Updated: 31-Aug-2026

Stock Rating

Is this stock worth it? Our ratings reveal the truth.

Wealth Insight New Issue

Serious stock insights. No fluff. No FOMO.

Recently Viewed

Clear All

PhaseBio Pharmaceuticals (PHAS) Key Ratios

Stock Card factsheet share-fund-plan-icon

$0.04

up-down-arrow $0.00 (5.26%)

As on 04-Jan-2023 09:30EDT

Market cap

info icon

$4 Mln

Revenue (TTM)

info icon

$-10 Mln

P/E Ratio

info icon

--

P/B Ratio

info icon

26.2

Div. Yield

info icon

0 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue 77.78 -97.99 -196.75 -270.33 --
EBIT -50.54 38.31 125.46 43.32 14.71
Net Profit -49.58 41.89 125.19 43.57 14.71
EPS -- -- -- -- --
Book Value -- -- -- -- --
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMDec-21Dec-20
EBIT-Margin info -11,056.95-9,038.30-262.20-1,204.12-30,350.00
Net Margin info -320.4611.28-210.48--736.16
Return on equity info -212.47-104.74--0.22-566.86
Return on Capital info -126.23-31.12--0.27-319.97
Return on Assets info -67.52-75.3834.34-0.24-148.38
Debt to Equity (x) info ----0.00-0.08-0.48

Profitability

View Detailed Peer Comparison

ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Dec-21
Dec-20
Dec-19
Dec-18
PhaseBio Pharmaceuticals (PHAS)
--
0.27
-319.97
-58.97
210.91
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

--

--

Profit after tax / Average Net worth * 100

Company Name
TTM
Dec-21
Dec-20
Dec-19
Dec-18
PhaseBio Pharmaceuticals (PHAS)
--
0.22
-566.86
-70.78
102.59
Peer Median
-40.40
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

34.34

Higher than Peers by 65.32

Profit after tax / Average Total assets * 100

Company Name
TTM
Dec-21
Dec-20
Dec-19
Dec-18
PhaseBio Pharmaceuticals (PHAS)
34.34
-0.24
-148.38
-53.94
-61.84
Peer Median
-30.98
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

-262.20

Lower than Peers by 178.58

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Dec-21
Dec-20
Dec-19
Dec-18
PhaseBio Pharmaceuticals (PHAS)
-262.20
-1,204.12
-30,350.00
-1,616.73
-2,982.34
Peer Median
-83.62
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

-210.48

Lower than Peers by 117.81

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Dec-21
Dec-20
Dec-19
Dec-18
PhaseBio Pharmaceuticals (PHAS)
-210.48
-1,210.15
736.16
-1,377.09
674.76
Peer Median
-92.67
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Profit Margin

0.00

Lower than Peers by 0.00

(Net profit + Depreciation) / Gross Sales * 100

Company Name
TTM
Dec-21
Dec-20
Dec-19
Dec-18
PhaseBio Pharmaceuticals (PHAS)
0.00
--
--
--
--
Peer Median
0.00
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Growth

View Detailed Peer Comparison

Revenue Growth

-196.75

Lower than Peers by 250.70

Year on year growth in net sales

Company Name
TTM
Dec-21
Dec-20
Dec-19
Dec-18
PhaseBio Pharmaceuticals (PHAS)
-196.75
-0.97
-0.86
2.53
--
Peer Median
53.95
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

125.46

Higher than Peers by 126.26

Year on year growth in operating profit (EBIT)

Company Name
TTM
Dec-21
Dec-20
Dec-19
Dec-18
PhaseBio Pharmaceuticals (PHAS)
125.46
99.87
-154.43
-91.60
-134.76
Peer Median
-0.80
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

125.19

Higher than Peers by 132.49

Year on year growth in profit after tax

Company Name
TTM
Dec-21
Dec-20
Dec-19
Dec-18
PhaseBio Pharmaceuticals (PHAS)
125.19
99.87
-151.14
-64.59
-132.71
Peer Median
-7.30
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Solvency

View Detailed Peer Comparison

Debt to Equity

--

--

Total debt / Net worth

Company Name
TTM
Dec-21
Dec-20
Dec-19
Dec-18
PhaseBio Pharmaceuticals (PHAS)
--
-0.08
-0.48
0.25
0.15
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

-0.04

--

(Short term borrowings / Net worth)

Company Name
TTM
Dec-21
Dec-20
Dec-19
Dec-18
PhaseBio Pharmaceuticals (PHAS)
-0.04
-0.06
-0.21
0.04
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

0.47

Lower than Peers by 5.34

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Dec-21
Dec-20
Dec-19
Dec-18
PhaseBio Pharmaceuticals (PHAS)
0.47
1.75
2.68
9.30
13.68
Peer Median
5.81
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

0.47

Lower than Peers by 5.23

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Dec-21
Dec-20
Dec-19
Dec-18
PhaseBio Pharmaceuticals (PHAS)
0.47
--
--
--
--
Peer Median
5.70
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

22.24

Higher than Peers by 24.32

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Dec-21
Dec-20
Dec-19
Dec-18
PhaseBio Pharmaceuticals (PHAS)
22.24
-137.72
-67.21
-35.47
-5.08
Peer Median
-2.09
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

--

--

Debtors outstanding / Net Sales * 100

Company Name
TTM
Dec-21
Dec-20
Dec-19
Dec-18
PhaseBio Pharmaceuticals (PHAS)
--
--
17.81
52.22
34.88
Peer Median
19.14
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

-0.12

Lower than Peers by 0.19

Sales / Average Total Assets

Company Name
TTM
Dec-21
Dec-20
Dec-19
Dec-18
PhaseBio Pharmaceuticals (PHAS)
-0.12
0.00
0.00
0.03
0.02
Peer Median
0.06
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Dec-21
Dec-20
Dec-19
Dec-18
PhaseBio Pharmaceuticals (PHAS)
--
1,922.19
736.21
113.40
127.40
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Dec-21
Dec-20
Dec-19
Dec-18
PhaseBio Pharmaceuticals (PHAS)
--
--
--
--
26.42
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Valuation

View Detailed Peer Comparison

Price / Book Value

26.18

Higher than Peers by 21.00

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Dec-21
Dec-20
Dec-19
Dec-18
PhaseBio Pharmaceuticals (PHAS)
26.18
--
--
--
--
Peer Median
5.18
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

--

--

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Dec-21
Dec-20
Dec-19
Dec-18
PhaseBio Pharmaceuticals (PHAS)
--
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

0.00

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Dec-21
Dec-20
Dec-19
Dec-18
PhaseBio Pharmaceuticals (PHAS)
0.00
-20.42
0.17
1.56
2.70
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

3

Lower than Peers by 143

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Dec-21
Dec-20
Dec-19
Dec-18
PhaseBio Pharmaceuticals (PHAS)
3
--
--
--
--
Peer Median
146
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...